Conditions: Mild Cognitive Impairment
Keywords: Mild Cognitive Impairment Memory Loss Alzheimer's Disease Brain Aging Ampalex® CX516
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 175
Healthy volunteers: no

Brief summary:
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.

Detailed description:

Arms:
arm 1: CX516 - 900 mg arm 2: Placebo

Interventions: intervention 1: CX516 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: